GlycoMimetics to Present at Biocentury’s Newsmakers in the Biotech Industry Conference
September 05 2017 - 9:00AM
Business Wire
GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that Chief
Executive Officer Rachel King will present at BioCentury’s
Newsmakers in the Biotech Industry Conference. The presentation
will take place on Friday, September 8, 2017 at 1:30 p.m. ET in
room 311 of the Millennium Broadway Hotel in New York City.
To access the live webcast and subsequent archived recordings
for the presentation, please visit
the GlycoMimetics website
at www.glycomimetics.com.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company
focused on the discovery and development of novel glycomimetic
drugs to address unmet medical needs resulting from diseases in
which carbohydrate biology plays a key role. GlycoMimetics' most
advanced drug candidate, rivipansel, a pan-selectin antagonist, is
being developed for the treatment of vaso-occlusive crisis in
sickle cell disease and is being evaluated in a Phase 3 clinical
trial being conducted by its strategic collaborator, Pfizer.
GlycoMimetics' wholly-owned drug candidate, GMI-1271, an
E-selectin antagonist, is being evaluated in an ongoing Phase 2
clinical trial as a potential treatment for AML and in a Phase 1
clinical trial for the treatment of multiple myeloma. The FDA
recently granted GMI-1271 Breakthrough Therapy designation
for the treatment of adult AML patients with
relapsed/refractory disease. GlycoMimetics has also recently
initiated a Phase 1 clinical trial with a third drug candidate,
GMI-1359, a combined CXCR4 and E-selectin
antagonist. GlycoMimetics is located in Rockville,
MD in the BioHealth Capital Region. Learn more
at www.glycomimetics.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170905005466/en/
GlycoMimetics, Inc.Investors:Shari Annes,
650-888-0902sannes@annesassociates.comorMedia:Jamie
Lacey-Moreira, 410-299-3310jamielacey@presscommpr.com
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Mar 2024 to Apr 2024
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Apr 2023 to Apr 2024